Latest News about BIIB
Recent news which mentions BIIB
Eisai Posts New Lecanemab Data From Mid-Stage Alzheimer's Trial
November 11, 2021
From Benzinga
Is Compass Pathways Stock a Once-in-a-Lifetime Bargain?
November 11, 2021
From Motley Fool
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
November 11, 2021
From Benzinga
3 Vaccine Stocks With Big Opportunities Outside of COVID-19
November 11, 2021
From Motley Fool
Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: Reuters
November 10, 2021
From Benzinga
This Company Says Its New Topical Therapy Trials Bringing Hope to People Exposed to Biofilm Bacteria
November 09, 2021
From Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
From Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
From Benzinga
Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
November 05, 2021
From Benzinga
What Investors Should Like About Eli Lilly's Q3 Update
November 04, 2021
From Motley Fool
Healthcare Stocks Subject to Government Policy
November 02, 2021
From Benzinga
Cassava Stock Could Jump More Than 200 Times
November 01, 2021
From InvestorPlace
Biogen Beat Earnings and Raised Guidance. Here's Why I Still Wouldn't Buy the Stock
October 29, 2021
Tickers
BIIB
From Motley Fool
Down 76%: Is Cortexyme Stock a Bargain?
October 28, 2021
From Motley Fool
Cortexyme's Alzheimer's Drug Fails -- 2 Lessons for Investors
October 28, 2021
From Motley Fool
Should Biogen Investors Be Preparing for the Worst?
October 27, 2021
From Motley Fool
10 Biggest Price Target Changes For Tuesday
October 26, 2021
From Benzinga
Was Atea Pharmaceutical's Flop Predictable?
October 26, 2021
From Motley Fool
3 Big Problems With Biogen's Q3 Results
October 23, 2021
From Motley Fool
Why Ionis Pharmaceuticals Stock Is Down 13% This Week
October 22, 2021
From Motley Fool
10 Biggest Price Target Changes For Thursday
October 21, 2021
From Benzinga
Abbot Labs and Biogen Outshine Novavax in the Health Care Sector
October 20, 2021
From Benzinga
The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review
October 20, 2021
From Benzinga
2 Stocks That Could Grow Your Portfolio Over the Next Decade
October 20, 2021
From Motley Fool
3 Biotech Stocks That Are Ridiculously Overpriced
October 20, 2021
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.